Pentixapharm Holding Ag · XETR:PTP
Pentixapharm — Q3 2025 Earnings Presentation
32 slides from Pentixapharm's earnings presentation, Nov 12, 2025
Slide 1: Third Quarter and First Nine Months 2025 Financial Results and Business Update
Third Quarter and First Nine Months 2025 Financial Results and Business Update Expanding the Boundaries of Radiopharmaceuticals November 12, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements based on the beliefs of Pentixapharm Holding AG management. Such statements reflect current views of Pentixapharm Holding AG with respect to future events and results and are subject to risks and uncertainties. Actual r
Slide 3: Expanding the Boundaries of Radiopharmaceuticals
Expanding the Boundaries of Radiopharmaceuticals Advanced clinical-stage Biotech R&D Model: Headquartered in Berlin, Germany Expertise and resources • Novel radiopharmaceuticals More than 20 • Strong clinical development expertise dedicated employees • Solid global regulatory strategy • High-quality
Slide 4: Radiotheranostics: A New Paradigm in Precision Medicine
Radiotheranostics: A New Paradigm in Precision Medicine Radiodiagnostics: High-resolution PET-CT imaging Imaging • Stratify patients for tailored treatment • Map disease distribution at baseline • Track tumor burden with precision Radiotheranostics Seamlessly combining imaging and therapy to improve
Slide 5: Positioned to Unlock New Opportunities in Rapidly Growing Global Radiopharmaceutical Market
Positioned to Unlock New Opportunities in Rapidly Growing Global Radiopharmaceutical Market Global Radiopharmaceutical Market Size1) Radiopharmaceutical Market By Region ~7–10% CAGR Latin America Middle East and Africa 1,92% 0,99% $6.7–7.5 bn Exp. $14–16 bn 2024–2025 2033–2034 Asia Pacific North Ame
Slide 6: A Sharper, More Focused Pentixapharm Following Completed Streamlining
A Sharper, More Focused Pentixapharm Following Completed Streamlining Q1 Q2 Q3 Q4 Myelo001 CXCR4 and CD24 Focus on clinical development in Program discontinued following Strategic re-orientation of non- high-value Indications portfolio prioritization clinical and clinical development September 2025:
Slide 7: Transforming Personalized Medicine: Investment Highlights
Transforming Personalized Medicine: Investment Highlights Driving Value as Advanced Clinical-Stage Company Flagship Pipeline Broadening impact of radiopharmaceuticals with Drives Near- and Long-Term Impact advanced pipeline addressing high value biology PentixaFor/Ther: Phase 3-ready diagnostic in t
Slide 8: Focused Competencies at the Core of the Development Value chain
Focused Competencies at the Core of the Development Value chain Pentixapharm Core Expertise and Value Drivers Value Inflection Diagnostic IND/ Clinical Clinical In-license Discovery Pre-clinical CTIS Phase 1 Phase 2 Clinical Phase 3 Including Radionuclide Theranostic Manufacturing • Regulatory strat
Slide 9: Targeting CXCR4: A Biologically Validated Target
Targeting CXCR4: A Biologically Validated Target From Oncology to Cardiology – CXCR4 Anchors Next-Generation Radiopharmaceuticals CXCR4: One of the most thoroughly researched biological targets of the last decade with a central role in the bone marrow CXCR4 Theranostic in Oncology: CXCR4 Diagnostics
Slide 10: Targeting CD24: Highly Specific Cancer Therapy
Targeting CD24: Highly Specific Cancer Therapy From Checkpoint Modulation to Targeted Radiotherapy – CD24 Antibody-Based Radioconjugates CD24: A growing body of translational and early clinical work positions CD24 as a new therapeutic gateway in oncology and immunology Therapeutic Role in Oncology:
Slide 11: Building Pipeline Momentum Across Oncology and Cardiology
Building Pipeline Momentum Across Oncology and Cardiology Lead Pre- IND/ Candidate Target Indication Optimization clinical CTIS Phase I Phase II Phase III Sponsor Radiodiagnostics Hypertension – Primary Aldosteronism PTF302 Ph3 ready PentixaFor PT-001 CXCR4 Cardiovascular IITs Hypertension – ⁶⁸Ga En
Slide 12: Upcoming Clinical Milestones Poised to Drive Significant Value
Upcoming Clinical Milestones Poised to Drive Significant Value 2025 2026 2027 2028 PTF302 PTF302 PTF302 PTF302 Cardiology FDA Scientific Open IND First 50 patients dosed Topline data PTF302 Advice Meeting expt. H1 2026 in U.S./EU expt. H1 2027 expt. H2 2028 Primary expt. Q4 2025 PT003: Aldosteronism
Slide 13: Pentixapharm Radiodiagnostics
Pentixapharm Radiodiagnostics Cardiology - Hypertension – Primary Aldosteronism November 2025 Pentixapharm・Investor Presentation 13
Slide 14: Transforming the Diagnostic Pathway in Primary Aldosteronism
Transforming the Diagnostic Pathway in Primary Aldosteronism Subtyping Subtyping Results Therapy Nonlateralizing PA Adrenal CT/ (mostly BAH) Adrenal Venous 65% of the cases Mineralpocorticoid Sampling (AVS) receptor antagonist (Lifelong medication) Standard of Care Lateralizing PA (mostly unilateral
Slide 15: Advancing Toward Phase III: Redefining Diagnosis in Primary Aldosteronism with PentixaFor
Advancing Toward Phase III: Redefining Diagnosis in Primary Aldosteronism with PentixaFor Adrenal Venous Sampling (AVS) Local subtyping for unilateral disease Unilateral Patient Confirmed Primary adrenalectomy follow-up Aldosteronism Local subtyping for unilateral disease 68[Ga]Ga-PentixaFor PET/CT
Slide 16: PTF302: Pioneering CXCR4 in Primary Aldosteronism
PTF302: Pioneering CXCR4 in Primary Aldosteronism 2026 2027 2028 2029 Type C FDA Advice EMA Prime Designation Registrational NDA / Market CXCR4 Radio- ⁶⁸Ga-PentixaFor Registrational Phase 3 ready Authorization Phase 1/2 IIT Program completed Phase 3 ready diagnostic in Cardiovascular Go / no-go crit
Slide 17: Pentixapharm Radiotheranostics
Pentixapharm Radiotheranostics Blood Cancers November 2025 Pentixapharm・EIB Presentation 17
Slide 18: PentixaFor / PentixaTher CXCR4-directed Radiotheranostics Transforming Bone Marrow Conditioning
PentixaFor / PentixaTher CXCR4-directed Radiotheranostics Transforming Bone Marrow Conditioning in Blood Cancers State-of-the-art bone marrow conditioning Precision CXCR4-directed radiotheranostics Before stem cell transplantation (SCT) Transform bone marrow conditioning PentixaFor radiodiagnostic:
Slide 19: Where the Need Is Greatest: Global Incidence of Blood Cancers
Where the Need Is Greatest: Global Incidence of Blood Cancers Requiring Bone Marrow Conditioning Global Incidence cases per year Central Nervous System Lymphoma ~10,000–12,000 Bone Marrow Conditioning & Acute Myeloid Leukemia ~145,000 Treatment Multiple Myeloma ~185,000 November 2025 Pentixapharm・Th
Slide 20: Pentilula IIT Phase 1/2 Study of PentixaTher in Relapsed/Refractory AML
Pentilula IIT Phase 1/2 Study of PentixaTher in Relapsed/Refractory Acute Myeloid Leukemia Phase I/II study assessing radioligand therapy with [177Lu]Lu-PentixaTher (PT-002) for relapsed/refractory CXCR4+ acute leukemia Primary Objective: To determine the MTD/DLT of Lu177-PentixaTher (PT-002) Timeli
Slide 21: Pentixapharm Radiotheranostics: Antibody Platform
Pentixapharm Radiotheranostics Antibody Platform November 2025 21 Pentixapharm・EIB Presentation
Slide 22: Monoclonal Antibodies Drive Innovation in Radiopharma Pipelines at Every Stage
Monoclonal Antibodies Drive Innovation in Radiopharma Pipelines at Every Stage of Development Peptide / Antibody Small Mini UDC Ligand Molecule Proteins ¹⁷⁷Lu ²²⁷Ac ²¹²Pb ¹³¹ ¹²³ I ⁶⁷Cu ⁹⁰Y ²¹¹At ¹⁶¹Tb ¹⁸⁵ ¹⁸⁶ Re ¹⁵³Sm UDC GT-008 Preclinical /Discover Phase 1 Phase 2 Phase 3 Commercialization www.li
Slide 23: Preclinical Proof-of-Concept Study Demonstrating CD24-Targeting GT-008 Tumor Selectivity
Preclinical Proof-of-Concept Study Demonstrating CD24-Targeting GT- 008 Tumor Selectivity and Anti-Tumor Activity 225 Ac-labeled GT-008 + 1500 Treatment Unlabelled GT-008 Vehicle Tumor volume [mm3] 225 225Ac-GT-008 10 kBq Ac-GT-008 10 kBq GT-008 Radioisotope GT-008 1000 225 225Ac-GT-008 3 kBq 3 kBq
Slide 24: Targeting CD24: Closing the Gap for Female Cancers
Targeting CD24: Closing the Gap for Female Cancers Great Investment and Partnering Opportunities [Market size (CAGR)] • Breast Cancer: $38.0 billion (9%) • Endometrial Cancer: $27.1 billion (6%) • Ovarian Cancer: $2.5 billion (2-14%) Asset for Still high unmet medical need: strategic partnering • Li
Slide 25: Pentixapharm Financials
Pentixapharm Financials Current Financial Position 25
Slide 26: Balance Sheet Third Quarter 2025
Balance Sheet Third Quarter 2025 in € thousands 31.12.2024 30.09.2025 in € thousands 31.12.2024 30.09.2025 Assets Liabilities and Equity Non-current assets Equity Other intangible assets 35.354 33.194 Subscribed capital 24.795 24.795 Property, plant and equipment 269 240 Capital reserves 37.475 37.4
Slide 27: Profit & Loss Third Quarter 2025
Profit & Loss Third Quarter 2025 in € thousands 01-09/2024 01-09/2025 Revenue 0 117 Income from the sale of rights/patents 0 0 Other operating income 0 482 Cost of materials and external services for research and development 0 -4.723 Personnel expenses 0 -4,072 Other operating expenses -171 -2.22 8
Slide 28: Cash Flow Statement Third Quarter 2025
Cash Flow Statement Third Quarter 2025 in € thousands 01-09/2024 01-09/2025 Cash flow from operating activities Profit/loss -171 -12.694 Adjustments for: Depreciation, amortization and impairment losses 0 2.803 Change in deferred taxes 0 -295 Income taxes paid 0 -53 Other non-cash expenses/income 0
Slide 29: Financial Guidance Full-Year 2025
Financial Guidance Full-Year 2025 Total Loss: €18 million FY 2025 R&D Personnel & Other Depreciation: Grants: Expenses: OPEX: €7 million €8 million €3.7 million €0.6 million November 2025 Pentixapharm・Third Quarter and First Nine Months 2025 29
Slide 30: Events After the Reporting Date
Events After the Reporting Date • After the reporting date of September 30, 2025, the Management Board of Pentixapharm Holding AG resolved in October 2025 to implement measures aimed at optimizing the organizational and cost structure. • These measures are intended to further increase operational ef
Slide 31: Transforming Personalized Medicine: Investment Highlights
Transforming Personalized Medicine: Investment Highlights Driving Value as Advanced Clinical-Stage Company Flagship Pipeline Broadening impact of radiopharmaceuticals with Drives Near- and Long-Term Impact advanced pipeline addressing high value biology PentixaFor/Ther: Phase 3-ready diagnostic in t
Slide 32: Thank you
Thank you www.pentixapharm.com